NCT00005810View on ClinicalTrials.gov

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

December 31, 2003

Study Completion Date

June 30, 2006

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

filgrastim

DRUG

carboplatin

DRUG

docetaxel

DRUG

estramustine phosphate sodium

Trial Locations (7)

10021

Memorial Sloan-Kettering Cancer Center, New York

21201

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

60637

University of Chicago Cancer Research Center, Chicago

94115-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

02115

Dana-Farber Cancer Institute, Boston

03756

Norris Cotton Cancer Center, Lebanon

27599-7295

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00005810 - Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | Biotech Hunter | Biotech Hunter